ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

abemaciclib

Also written as “Abemaciclib”, “LY2835219” and “Abemaciclib Tablet (Test Formulation)”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Neoplasm Metastasis · Sarcoma, Ewing, led by 2 companies.

Drug pageAbemaciclib: every studyAll 156 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 12, 201949 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only4814 open or runningphase 4since Jun 12, 2019Jul 12, 2011Nov 2026phase 1 · NCT07818967
Hoffmann-La Roche10 open or runningphase 2since Sep 11, 2017Sep 11, 2017none ahead

Also a collaborator on its studies: Bayer and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2017First study: phase 2 study in Breast NeoplasmsFirst studyNCT03280563 · 144 enrolled · United States, Israel, South Korea

TargetBeta

CDK4 →CDK6 →read by rule
“The mesylate salt of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets the cyclin D1-CDK4 and cyclin D3-CDK6 cell cycle pathway, ”NCIt, by rule
“Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
palbociclibrulePfizerphase 436
trilaciclibrulePharmacosmosphase 414
culmerciclibSino Biopharmaceuticalphase 311
narazaciclibrulehangzhou-hanx-biopharmaceuticals-ltdphase 24
vustanaciclibregor-pharmaceuticals-incphase 23

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03280563Breast Neoplasms · United States, Israel, South Korea2CompletedSep 26, 2024144

How it is read

Names in the registry

  • “Abemaciclib”, 41 entries
  • “LY2835219”, 5 entries
  • “Abemaciclib Tablet (Test Formulation)”, 2 entries
  • “Abemaciclib Tablet (Reference Formulation)”, 1 entry
  • “Abemaciclib Oral Granules (Test Formulation)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.